Consistent with these findings, we have also validated the findings that CD14+ depletion deleteriously impacts on CLL cell viability, and we show for the first time in patient samples using selective small-molecule inhibitors that this phenomenon is mimicked by CSF1R inhibition, suggesting a new potential therapeutic route to target the CLL microenvironment. This evidence concerns the gene CD14 and B-cell chronic lymphocytic leukemia.